Emmes, a leading Clinical Research Organization (CRO) dedicated to advancing public health and biopharmaceutical innovation, has taken a major step forward with the acquisition of Essex Management. Essex is a provider of top-notch bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is part of Emmes’ ongoing mission to provide its clients with the best possible solutions and expand its services. With the addition of Essex, Emmes will be able to open new doors with government agencies and provide innovative data strategies for biopharma clients.
The merger of Emmes and Essex will create a clinical research powerhouse that is unrivaled in the industry. With Essex’s technology skills and Emmes’ innovative data and advanced analytics solutions, the CRO will be better equipped to address global health challenges and provide innovative solutions to its clients.
Essex’s reputation as a technology catalyst in the life sciences, combined with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will result in a winning combination that will drive growth and advance clinical research in new and exciting ways.
Author
